G28-5 sFv-PE40

Drug Profile

G28-5 sFv-PE40

Alternative Names: G28-5s Fv-PE40

Latest Information Update: 18 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Immunotoxins
  • Mechanism of Action CD40 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 18 Jan 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 28 May 2001 No-Development-Reported for Cancer in USA (Unknown route)
  • 05 Oct 1998 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top